(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases...
Stats | |
---|---|
本日の出来高 | 375 912 |
平均出来高 | 247 981 |
時価総額 | 42.44M |
EPS | $0 ( 2024-03-21 ) |
次の収益日 | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.608 |
ATR14 | $0.0360 (5.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-29 | Fairmount Funds Management Llc | Buy | 24 670 | Common Stock |
2023-09-26 | Fairmount Funds Management Llc | Buy | 30 000 | Common Stock |
2023-09-22 | Randhawa Simrat | Buy | 2 000 | Common Stock |
2023-09-21 | Randhawa Simrat | Buy | 2 000 | Common Stock |
2023-09-19 | Fairmount Funds Management Llc | Buy | 30 000 | Common Stock |
INSIDER POWER |
---|
-68.65 |
Last 94 transactions |
Buy: 3 902 024 | Sell: 4 691 992 |
ボリューム 相関
Magenta Therapeutics Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Magenta Therapeutics Inc 相関 - 通貨/商品
Magenta Therapeutics Inc 財務諸表
Annual | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-23.05 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-23.05 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.290 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.710 |
Financial Reports:
No articles found.
Magenta Therapeutics Inc
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。